Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation (EBVALLO)
Epstein-Barr Viraemia, Hematologic Diseases, Allogeneic Disease
About this trial
This is an interventional basic science trial for Epstein-Barr Viraemia focused on measuring Allogenic cell stem transplant (HSCT), EBV-induced lymphoproliferation, Epigenetic
Eligibility Criteria
Inclusion Criteria:
Retrospective study:
- Patient who underwent HSCT, in Saint-Antoine hospital,
- between 2010-2015,
- treated by rituximab for high level EBV-DNAemia (above 3.3 log copies/mL).
Prospective study:
- Patients who underwent HSCT, in Saint-Antoine hospital and la Pitié-Salpêtrière,
- in 2017-2018,
- treated by rituximab for high level EBV-DNAemia (above 10 000c/mL),
- And/or having post-transplant lymphoproliferative diseases(PTLD)
Exclusion Criteria:
- Refusal to sign the informed consent
- Patient non-beneficiary of the Social Security system
Sites / Locations
- Service d'hématologie Clinique
Arms of the Study
Arm 1
Other
EBV+ allograft population
Retrospective study (n=80) : Patient who underwent HSCT, in Saint-Antoine hospital, between 2010-2015, treated by rituximab for high level EBV-DNAemia (above 3.3 log copies/mL). Prospective study (n=58) : Patients who underwent HSCT, in Saint-Antoine hospital and la Pitié-Salpêtrière, in 2016-2017, treated by rituximab for high level EBV-DNAemia (above 10 000c/mL), And/or having post-transplant lymphoproliferative diseases(PTLD) Concerned population Allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients with a high Epstein-Barr virus (EBV) viral load